UBS AM
LEGN icon

UBS AM’s Legend Biotech LEGN Stock Holding History

UBS AM’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.59M Buy
+228,229
New +$6.16M ﹤0.01% 1477
2025
Q3 		– Sell
-146,322
Closed -$5.19M – 2457
2025
Q2 		$5.19M Buy
146,322
+32,867
+29% +$1.07M ﹤0.01% 1689
2025
Q1 		$3.85M Sell
113,455
-22,983
-17% -$824K ﹤0.01% 1696
2024
Q4 		$4.44M Buy
136,438
+36,181
+36% +$1.5M ﹤0.01% 1665
2024
Q3 		$4.89M Sell
100,257
-6,276
-6% -$334K ﹤0.01% 1581
2024
Q2 		$4.72M Sell
106,533
-223,790
-68% -$10.3M ﹤0.01% 1524
2024
Q1 		$18.5M Buy
330,323
+29,917
+10% +$1.8M 0.01% 809
2023
Q4 		$18.1M Buy
300,406
+38,001
+14% +$2.41M 0.01% 794
2023
Q3 		$17.6M Buy
262,405
+47,947
+22% +$3.33M 0.01% 789
2023
Q2 		$10.3M Hold
214,458
– – 0.01% 963
2023
Q1 		$10.3M Buy
214,458
+31,961
+18% +$1.56M 0.01% 963
2022
Q4 		$9.11M Sell
182,497
-312,379
-63% -$15.1M ﹤0.01% 977
2022
Q3 		$20.2M Buy
494,876
+9,737
+2% +$457K 0.01% 762
2022
Q2 		$26.7M Buy
485,139
+320,007
+194% +$13.5M 0.01% 674
2022
Q1 		$6M Buy
165,132
+44,798
+37% +$1.77M ﹤0.01% 1277
2021
Q4 		$5.61M Buy
+120,334
New +$6.1M ﹤0.01% 1362
2020
Q3 		– Sell
-25,000
Closed -$1.06M – 2501
2020
Q2 		$1.06M Buy
+25,000
New +$977K ﹤0.01% 1775

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

UBS AM's LEGN Position: Q2 2026 in Review

UBS AM opened a new position in Legend Biotech (LEGN) in Q2 2026: 228,229 shares worth $6.59M. The stake represents ﹤0.01% of the portfolio and ranks #1477 among its holdings. This is a return to the name: UBS AM previously reported a position in LEGN as recently as Q2 2025.

UBS AM first reported a position in LEGN in Q2 2020 and has held it in 17 quarters since. The position peaked at $26.7M in Q2 2022. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • UBS AM held 228,229 shares of Legend Biotech worth $6.59M as of Q2 2026.
  • Legend Biotech was a new UBS AM position in Q2 2026.
  • Legend Biotech made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1477 holding.
  • UBS AM first reported a position in Legend Biotech in Q2 2020 and has held it in 17 quarters since.
  • UBS AM's Legend Biotech position peaked at $26.7M in Q2 2022.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.